



Health  
Canada Santé  
Canada

Your health and  
safety... our priority.

Votre santé et votre  
sécurité... notre priorité.

Registration Decision

RD2016-20

# Metofluthrin

*(publié aussi en français)*

**2 June 2016**

This document is published by the Health Canada Pest Management Regulatory Agency. For further information, please contact:

Publications  
Pest Management Regulatory Agency  
Health Canada  
2720 Riverside Drive  
A.L. 6607 D  
Ottawa, Ontario K1A 0K9

Internet: [pmra.publications@hc-sc.gc.ca](mailto:pmra.publications@hc-sc.gc.ca)  
[healthcanada.gc.ca/pmra](http://healthcanada.gc.ca/pmra)  
Facsimile: 613-736-3758  
Information Service:  
1-800-267-6315 or 613-736-3799  
[pmra.infoserv@hc-sc.gc.ca](mailto:pmra.infoserv@hc-sc.gc.ca)

Canada 

ISSN: 1925-0932 (print)  
1925-0940 (online)

Catalogue number: H113-25/2016-20E (print version)  
H113-25/2016-20E-PDF (PDF version)

**© Her Majesty the Queen in Right of Canada, represented by the Minister of Health Canada, 2016**

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of the Minister of Public Works and Government Services Canada, Ottawa, Ontario K1A 0S5.

## Registration Decision Statement<sup>1</sup> for Metofluthrin

Health Canada's Pest Management Regulatory Agency (PMRA), under the authority of the *Pest Control Products Act* and Regulations, is granting full registration for the sale and use of SumiOne Technical Grade and OFF! Clip On Mosquito Repellent, containing the technical grade active ingredient metofluthrin, as a personal insect repellent.

This decision is consistent with the Proposed Registration Decision PRD2016-09, *Metofluthrin*, which contains a detailed evaluation of the information submitted in support of this registration. The evaluation found that, under the approved conditions of use, the products have value and do not present an unacceptable risk to human health or the environment. See Appendix I for a summary of comments received during the consultation process as well as the PMRA's response to these comments.

### Other Information

The relevant test data on which the decision is based (as referenced in PRD2016-09, *Metofluthrin*) are available for public inspection, upon application, in the PMRA's Reading Room (located in Ottawa). For more information, please contact the PMRA's Pest Management Information Service by phone (1-800-267-6315) or by e-mail ([pmra.infoserv@hc-sc.gc.ca](mailto:pmra.infoserv@hc-sc.gc.ca)).

Any person may file a notice of objection<sup>2</sup> regarding this registration decision within 60 days from the date of publication of this Registration Decision. For more information regarding the basis for objecting (which must be based on scientific grounds), please refer to the Pesticides and Pest Management portion of the Health Canada's website (Request a Reconsideration of Decision) or contact the PMRA's Pest Management Information Service.

---

<sup>1</sup> "Decision statement" as required by subsection 28(5) of the *Pest Control Products Act*.

<sup>2</sup> As per subsection 35(1) of the *Pest Control Products Act*.



## **Appendix I    Comments and Responses**

### **Comment**

A comment was made in which concern was expressed over the PMRA's approach for the cancer risk assessment. In published PMRA documents for metofluthrin, it was concluded that although the proposed mode of action (phenobarbital-like) for rat liver tumour formation was deemed plausible, the overall weight of evidence to support it was deemed inadequate, and thus the PMRA considered the tumours relevant for the cancer risk assessment. Consequently, a linear low-dose extrapolation was utilized. The commenter was of the opinion that the body of available data, including expert opinions as well as recent studies and information in the published scientific literature, confirm the mode of action and thus the tumours are not relevant for human cancer risk assessment.

### **Response**

The cited information/studies, which includes information that was not available at the time of the original toxicology review, has yet to be provided to the PMRA. Until such time as the PMRA receives this information, the approach to the cancer risk assessment will remain as is.